UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that collates work from the two companies’ ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

However, this treatment is not always effective in some patients. Now scientists have investigated a different antibody type, IgE, which activates the patient's immune system in different ways to IgG.

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, says it has completed the ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

However, this treatment is not always effective in some patients. Now scientists have investigated a different antibody type, IgE, which activates the patient's immune system in different ways to IgG.

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...